GEMINI 1
The purpose of this study is to assess the efficacy of two drug treatments measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS.
The purpose of this study is to assess the efficacy of two drug treatments measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS.
The purpose of this study is to investigate the impact of genetic and non-genetic risk factors for Alzheimer’s disease (AD), evaluate differential
effects of sex on AD risk, and predict diagnosis of AD using dementia risk scores derived from genetic and nongenetic risk factors.
The purpose of this study is to evaluate the feasibility of using repetitive transcranial magnetic stimulation (rTMS) to treat depression.
The purpose of this study is to is to examine the effects of 12 weeks of high intensity interval training on the cognitive health of perimenopausal woman.
The purpose of this study is to evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS).
The purpose of this study is to explore the use of bright light therapy as maintenance treatment for depression to determine if it is
The purpose of this study is to determine ways to meet the social needs related to loneliness and isolation in seniors with dementia while examing barriers and successes surrounding the use of a robot-assisted, virtual care solution within care settings.
The purpose of this study is to evaluate the use of an oral multi-strain probiotic in the treatment of anxiety in individuals with Parkinson's Disease.
The purpose of this study is to evaluate the efficacy and safety of the drug pridopidine in patients with early stage manifest Huntington Disease.
The purpose of this study is to learn about biomarkers (biological features such as proteins, genes, and brain images that indicate the state of a disease in a person), and how they can help predict treatment outcomes in patients with clinical depression.
The purpose of the study is to better understand the safety of using combination antithrombotic therapy in patients with high risk transient ischemic attack (TIA) or ischemic stroke secondary to ICAD (intracranial atherosclerotic disease) for prevention of recurrent stroke.
The purpose of the study is to evaluate the long-term safety and tolerability of aducanumab in participants who had previously participated in aducanumab studies.
The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).
This project will explore the effect of exercise on brain energetics using functional MRI and PET imaging in people with Parkinson's disease.
The purpose of this study is to assess the safety and tolerability of valbenazine for the treatment of chorea associated with Huntington's Disease.
The purpose of the study is to examine the feasibility and effectiveness of a 4-week lower extremity telerehabilitation protocol with aims to improve lower extremity recovery amoung community-living stroke survivors.
This randomized controlled trial will enrol patients with acute severe brain injury who pass a spontaneous breathing trial but have decreased level of consciousness. It will directly compare (1) prompt extubation vs. (2) prompt tracheostomy vs. (3) usual care, with extubation or tracheostomy timed according to physicians' discretion. The primary outcome will be ICU free days (days spent alive and outside an ICU).
The purpose of the main study is to investigate adverse drug reactions from multiple sclerosis (MS) disease modifying drugs by understanding the genetic factors that contribute to their cause.
The sub-study investigates how the MS disease modifying drugs affect microbes in the gut and how human DNA affects the changes in the gut microbes following drug treatment. We are also interested in how gut microbes might relate to progressive MS.
This is an observational study designed to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health.
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).